Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arrowhead Pharma (NQ: ARWR ) 23.91 -0.78 (-3.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,052,135 Open 24.27 Bid (Size) 23.30 (3) Ask (Size) 24.50 (2) Prev. Close 24.69 Today's Range 23.45 - 24.34 52wk Range 20.67 - 39.83 Shares Outstanding 105,736,200 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? June 03, 2024 Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran. Via Benzinga Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday June 03, 2024 Via Benzinga Performance YTD -22.90% -22.90% 1 Month -4.36% -4.36% 3 Month -27.98% -27.98% 6 Month -2.53% -2.53% 1 Year -33.10% -33.10% More News Read More Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome June 03, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences May 31, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia May 29, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia May 28, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma May 20, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 May 14, 2024 Via InvestorPlace ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 May 09, 2024 Via InvestorPlace Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results May 09, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 10, 2024 Via Benzinga Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment May 02, 2024 Via Benzinga Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma May 02, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences April 29, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars April 26, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results April 24, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease April 24, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Turnstone Biologics Appoints William Waddill to its Board of Directors April 16, 2024 From Turnstone Biologics Corp. Via GlobeNewswire Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo April 07, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024 April 05, 2024 Via InvestorPlace NetApp, Zoom Video And 2 Other Stocks Insiders Are Selling April 04, 2024 Via Benzinga Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) April 01, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data March 25, 2024 From Arrowhead Pharmaceuticals, Inc. Via Business Wire 7 Biotech Stocks to Buy as Sector Rotation Ramps Up March 13, 2024 Via InvestorPlace The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 March 11, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
